Particulars (Rupees in Crores.) | Sept-2024 | Mar-2024 | Sept-2023 | Mar-2023 | Sept-2022 |
---|---|---|---|---|---|
Gross Sales | 3,462.6 | 3,411.6 | 3,233.2 | 3,194.1 | 3,025.2 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 3,462.6 | 3,411.6 | 3,233.2 | 3,194.1 | 3,025.2 |
Other Operating Income | 21.4 | 24.1 | 34 | 36.4 | 26 |
Other Income | 417.4 | 66.7 | 26.1 | 26.2 | 24.4 |
Total Income | 3,901.4 | 3,502.4 | 3,293.3 | 3,256.7 | 3,075.6 |
Total Expenditure | 2,943.2 | 3,115.2 | 2,855.8 | 2,862.6 | 2,699.7 |
PBIDT | 958.2 | 387.2 | 437.5 | 394.1 | 375.9 |
Interest | 132 | 144.3 | 128 | 106.3 | 81.9 |
PBDT | 826.2 | 242.9 | 309.5 | 287.8 | 294 |
Depreciation | 182.1 | 195.6 | 186.3 | 365.5 | 188.5 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 66.1 | 153.2 | 49.4 | 49.6 | 131.5 |
Deferred Tax | -6.3 | -110.5 | 5.7 | -10.7 | -77.7 |
Reported Profit After Tax | 584.3 | 4.6 | 68.1 | -116.6 | 51.7 |
Minority Interest After NP | -0.6 | -3.6 | -0.8 | -3.1 | -0.8 |
Net Profit after Minority Interest | 584.9 | 8.2 | 68.9 | -113.5 | 52.5 |
Extra-ordinary Items | 342.53 | -168.9 | 0 | 0 | 14 |
Adjusted Profit After Extra-ordinary item | 242.37 | 177.1 | 68.9 | -113.5 | 38.5 |
EPS (Unit Curr.) | 36.91 | 0.52 | 4.34 | 0 | 3.3 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 15.8 | 15.8 | 15.8 | 15.9 | 15.9 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 27.67 | 11.34 | 13.53 | 12.33 | 12.42 |
PBDTM(%) | - | - | - | - | - |
PATM(%) | 16.87 | 0.13 | 2.1 | -3.65 | 1.7 |
This FDA audit confirms compliance with regulatory standards, enhancing the credibility of Jubilant's operations in the United States.
Jubilant Pharmova Ltd has gained a total of 126% in the last one year, and almost 75% gain since the beginning of the year.
Here are some of the stocks that may see significant price movement today: Tata Motors, Reliance Industries, IREDA, etc.
Drug company Jubilant Pharmova Ltd will acquire an 80% stake in Pierre Fabre Laboratories' Research & Development Centre in Saint Julien, France.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.